<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q/A
(MARK ONE)
[/X/] Quarterly Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
For the quarterly period ended SEPTEMBER 30, 2000 or
[ ] Transition Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
For the transition period from ___________ to ___________
Commission File Number: 33-26398
--------
ALARIS MEDICAL, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 13-3492624
------------------------------ -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
10221 Wateridge Circle, San Diego, CA 92121
-----------------------------------------------------
(Address of principal executive offices) (Zip Code)
(858) 458-7000
----------------------------------------------------
(Registrant's telephone number, including area code)
----------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes: /X/ No: _____
On November 9, 2000, 58,844,834 shares of Registrant's Common Stock were
outstanding, excluding shares held in Treasury.
The purpose of this Form 10Q/A is to amend Item 6 to add an exhibit as of
September 30, 2000.
Page 1 of 27
<PAGE>
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
10.21 -- Amendment No. 7 and Consent to the Bank Credit Agreement dated
as of August 28, 2000, among ALARIS Medical Inc., ALARIS Medical
Systems, Inc., the financial institutions party to the Credit
Agreement, Bankers Trust Company and Banque Paribas.
27 -- Financial Data Schedule (previously filed)
-----------------------------------------
(b) Reports on Form 8-K
During the quarter ended September 30, 2000 the Company filed a report on Form
8-K dated September 15, 2000. This report contained information and pro forma
financial statements related to the sale of the Instromedix division to Card
Guard Technologies, Inc.
- 26 -
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ALARIS MEDICAL, INC.
--------------------
(REGISTRANT)
Date: December 4, 2000 By: /s/ WILLIAM C. BOPP
--------------------
William C. Bopp
Senior Vice President and Chief Financial Officer
- 27 -
